American Society of Hirudotherapy

Hementin

Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Hementin compared with other characterized leech-derived compoundsHementin80 kDaHementerin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLHyal (Leech Hyaluronidase)50 kDa
Molecular weight (kilodaltons) of Hementin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Hementin's in vitro fibrinogenolytic activity does not establish clinical efficacy as a thrombolytic. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.

Molecular Profile

Category
Fibrinolytic
Evidence tier
Preclinical
Molecular weight
80,000 Da
Source species
Haementeria ghilianii (giant Amazon leech)
Discovered
1984 · Malinconico, Budzynski et al.
Hementin molecular structure

Biological Targets

  • fibrinogen Aα and Bβ chains

Key Citations

  1. Malinconico SM et al. (1984), Thromb Res · PMID 6387015

External Resources

    Related Fibrinolytic Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.